美国 · SEC FORM 4
Pharvaris N.V.
PHVS · Nasdaq · CIK 0001830487 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
119 同一窗口内观察到的 Form 4 交易行
65 sales · 54 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
Showing the six most active owners; 4 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot.—
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 2,007,998
- 上期报告
- 1,784,789
- 日均成交量
- 707,991
- 回补天数
- 2.8
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
本地 Form 4 历史中没有合资格的代码 P 股票买入。
Form 4 申报证据
126 transaction lines in the latest 365-day window; 126 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-12 | Lu Peng | 代扣税 (F) | Common Stock | 117 | USD 31.10 | USD 3,639 | SEC 申报 ↗ |
| 2026-10-11 | Lu Peng | 代扣税 (F) | Common Stock | 109 | USD 31.10 | USD 3,390 | SEC 申报 ↗ |
| 2026-09-23 | Monges Viviane | 卖出 (S) | Common Stock | 11,969 | USD 33.05 | USD 395,575 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-12 | Lu Peng | 代扣税 (F) | Common Stock | 117 | USD 31.10 | USD 3,639 | SEC 申报 ↗ |
| 2026-10-11 | Lu Peng | 代扣税 (F) | Common Stock | 109 | USD 31.10 | USD 3,390 | SEC 申报 ↗ |
| 2026-09-23 | Monges Viviane | 卖出 (S) | Common Stock | 11,969 | USD 33.05 | USD 395,575 | SEC 申报 ↗ |
| 2026-09-23 | Monges Viviane | 期权行权/转换 (M) | Common Stock | 11,969 | USD 8.05 | USD 96,350 | SEC 申报 ↗ |
| 2026-09-22 | Schikan Johannes Gerardus Christiaan Petrus | 卖出 (S) | Common Stock | 800 | USD 36.19 | USD 28,952 | SEC 申报 ↗ |
| 2026-09-22 | Schikan Johannes Gerardus Christiaan Petrus | 期权行权/转换 (M) | Common Stock | 800 | USD 20.00 | USD 16,000 | SEC 申报 ↗ |
| 2026-09-22 | Lu Peng | 期权行权/转换 (M) | Common Stock | 45,308 | USD 2.59 | USD 117,348 | SEC 申报 ↗ |
| 2026-09-21 | Nassif David W. | 卖出 (S) | Common Stock | 6,000 | USD 36.47 | USD 218,820 | SEC 申报 ↗ |
| 2026-09-21 | Nassif David W. | 赠与 (G) | Common Stock | 500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-09-17 | Schikan Johannes Gerardus Christiaan Petrus | 卖出 (S) | Common Stock | 200,000 | USD 35.00 | USD 7,000,000 | SEC 申报 ↗ |
| 2026-09-17 | Modig Berndt | 期权行权/转换 (M) | Common Stock | 300,000 | USD 35.00 | USD 10,500,000 | SEC 申报 ↗ |
| 2026-09-17 | Lu Peng | 卖出 (S) | Common Stock | 100,000 | USD 35.00 | USD 3,500,000 | SEC 申报 ↗ |
| 2026-09-17 | Lu Peng | 期权行权/转换 (M) | Common Stock | 100,000 | USD 2.59 | USD 259,000 | SEC 申报 ↗ |
| 2026-09-17 | Lesage Anne | 卖出 (S) | Common Stock | 20,000 | USD 38.27 | USD 765,400 | SEC 申报 ↗ |
| 2026-09-17 | Glassman Robert | 卖出 (S) | Common Stock | 14,493 | USD 38.56 | USD 558,850 | SEC 申报 ↗ |
| 2026-09-17 | Glassman Robert | 期权行权/转换 (M) | Common Stock | 14,493 | USD 18.14 | USD 262,903 | SEC 申报 ↗ |
| 2026-09-17 | Bjork Elisabeth | 卖出 (S) | Common Stock | 52,500 | USD 37.89 | USD 1,989,225 | SEC 申报 ↗ |
| 2026-09-17 | Bjork Elisabeth | 期权行权/转换 (M) | Common Stock | 52,500 | USD 15.64 | USD 821,100 | SEC 申报 ↗ |
| 2026-09-15 | Glassman Robert | 卖出 (S) | Common Stock | 8,667 | USD 38.27 | USD 331,686 | SEC 申报 ↗ |
| 2026-09-15 | Glassman Robert | 期权行权/转换 (M) | Common Stock | 8,667 | USD 22.31 | USD 193,361 | SEC 申报 ↗ |
| 2026-09-15 | Abele Stefan Andreas | 卖出 (S) | Common Stock | 46,400 | USD 38.17 | USD 1,771,236 | SEC 申报 ↗ |
| 2026-09-15 | Abele Stefan Andreas | 期权行权/转换 (M) | Common Stock | 45,000 | USD 16.40 | USD 738,000 | SEC 申报 ↗ |
| 2026-09-15 | Souverijns Wim | 卖出 (S) | Common Stock | 6,090 | USD 38.99 | USD 237,449 | SEC 申报 ↗ |
| 2026-09-14 | Souverijns Wim | 卖出 (S) | Common Stock | 20,000 | USD 39.31 | USD 786,200 | SEC 申报 ↗ |
| 2026-09-14 | Souverijns Wim | 期权行权/转换 (M) | Common Stock | 20,000 | USD 17.43 | USD 348,600 | SEC 申报 ↗ |
| 2026-09-14 | Modig Berndt | 卖出 (S) | Common Stock | 2,291 | USD 39.40 | USD 90,265 | SEC 申报 ↗ |
| 2026-09-14 | Lu Peng | 代扣税 (F) | Common Stock | 117 | USD 38.02 | USD 4,448 | SEC 申报 ↗ |
| 2026-09-11 | Lu Peng | 卖出 (S) | Common Stock | 15,000 | USD 40.13 | USD 601,950 | SEC 申报 ↗ |
| 2026-09-11 | Lu Peng | 期权行权/转换 (M) | Common Stock | 15,000 | USD 2.59 | USD 38,850 | SEC 申报 ↗ |
| 2026-09-11 | Lu Peng | 代扣税 (F) | Common Stock | 109 | USD 37.51 | USD 4,089 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | PHVS |
| CIK | 0001830487 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 126 transaction lines from 2026-04-01 to 2026-10-12 0 P purchase lines · 68 S sale lines · 58 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.